# Temodar and Sutent as Therapy for Melanoma

> **NCT00304200** · PHASE1,PHASE2 · TERMINATED · sponsor: **Northern California Melanoma Center** · enrollment: 7 (actual)

## Conditions studied

- Metastatic Malignant Melanoma

## Interventions

- **DRUG:** Temozolomide and SU11248

## Key facts

- **NCT ID:** NCT00304200
- **Lead sponsor:** Northern California Melanoma Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2007-10
- **Final completion:** 2009-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Funding was inadequate to continue; Companies requested closure.
- **Last updated:** 2009-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00304200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00304200, "Temodar and Sutent as Therapy for Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00304200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*